GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

cizutamig   Click here for help

GtoPdb Ligand ID: 14514

Synonyms: CD3med FIT-Ig [2] | EMB-06 | EMB06
Immunopharmacology Ligand
Compound class: Antibody
Comment: Cizutamig (EMB-06) is a humanized B-cell maturation antigen (BCMA; TNFRSF17)-CD3e bispecific antibody that is designed to act as a T cell engager (TCE) [2], to promote depletion of BCMA-expressing B cells and plasma cells for the treatment of autoimmune diseases and B cell malignancies.
No information available.
Summary of Clinical Use Click here for help
Cizutamig (EMB-06) was progressed as a clinical candidate, for the treatment of autoimmune diseases and myeloma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04735575 A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma Phase 1/Phase 2 Interventional Shanghai EpimAb Biotherapeutics Co., Ltd. 1
NCT07353450 A Study of Cizutamig for Patients With Ulcerative Colitis Early Phase 1 Interventional Ruijin Hospital
NCT07215663 Clinical Study of Cizutamig in Systemic Lupus Erythematosus Phase 1 Interventional Candid Therapeutics
NCT07215650 Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) Phase 1 Interventional Candid Therapeutics
NCT06946199 An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis Phase 1 Interventional Union Hospital, Tongji Medical College, Huazhong University of Science and Technology